The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Supplement berberine is hailed as nature's answer to GLP-1 weight loss drugs, but is it safe and will it truly make a ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like Ozempic and Wegovy. In phase III trials it significantly lowered blood ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage study, marking another weaker-than-expected result for an oral ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.